All News
Filter News
Found 808,690 articles
-
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
11/4/2021
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA ® Electronic Health Records System
-
Quidel Reports Third Quarter 2021 Financial Results
11/4/2021
Quidel Corporation announced today financial results for the third quarter ended September 30, 2021.
-
GenBody’s Anterior Nasal Swab COVID-19 Antigen Test Granted FDA Emergency Use Authorization as Part of an Effort to Meet Increased National Demand Amid Rapid Test Shortage
11/4/2021
Nov. 4, 2021 12:00 UTC GenBody’s direct anterior nasal swab COVID-19 antigen test becomes the company’s second test to receive FDA Emergency Use Authorization
-
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
11/4/2021
Ambrx Biopharma Inc. today announced the first patient has been dosed in its global ACE-Breast-03 Phase 2 clinical study of ARX788 in patients with HER2-positive metastatic breast cancer.
-
Galecto Reports Third Quarter Operating and Financial Results
11/4/2021
Galecto, Inc. today announced its operating and financial results for the quarter ended September 30, 2021.
-
Better Therapeutics Appoints Thiago Licias de Oliveira as Its Chief People Officer
11/4/2021
Better Therapeutics, Inc. today announced the appointment of Thiago Licias de Oliveira as its Chief People Officer.
-
FDA Awards Breakthrough Device Designation to the ReWalk ReBoot Soft Exo-Suit
11/4/2021
ReWalk Robotics, Ltd. today announced its ReBoot device has been granted designation as a Breakthrough Device by the Food and Drug Administration (FDA).
-
Edesa Biotech Extends COVID-19 Clinical Study to Poland
11/4/2021
Edesa Biotech, Inc. today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody candidate, designated EB05
-
Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results
11/4/2021
Checkpoint Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2021.
-
Tabula Rasa HealthCare Reports Third Quarter 2021 Results
11/4/2021
Tabula Rasa HealthCare, Inc. ("TRHC") (Nasdaq: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the third quarter ended September 30, 2021.
-
The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc.
11/4/2021
Codexis, Inc. today announced a combined $10 million investment enabled by their SynBio Innovation Accelerator in the Series B funding round of Molecular Assemblies, Inc.
-
Mainz Biomed N.V. Announces Pricing of Initial Public Offering
11/4/2021
Mainz Biomed N.V. announced today the pricing of its initial public offering of 2,000,000 ordinary shares at a price of $5.00 per share to the public for a total of $10,000,000 of gross proceeds to the Company.
-
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/4/2021
Arbutus Biopharma Corporation today reports its third quarter 2021 financial results and provides a corporate update.
-
Guardant Health Reports Third Quarter 2021 Financial Results
11/4/2021
Guardant Health, Inc. today reported financial results for the quarter ended September 30, 2021.
-
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
11/4/2021
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that Thierry Chauche will become Chief Financial Officer effective December 1, 2021 and Andrew Drechsler will be retiring, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.
-
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
11/4/2021
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, provided a business update and reported financial results for the third quarter of 2021.
-
Adaptimmune Reports 2021 Third Quarter Financial Results and Business Update
11/4/2021
Adaptimmune Therapeutics plc today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Biotricity Releases Fiscal 2022 Second Quarter Financial Results
11/4/2021
Biotricity Inc. today announced financial results for its 2022 fiscal year's second quarter ended September 30, 2021.
-
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights
11/4/2021
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, announced financial results for the third quarter ended September 30, 2021, and reviewed recent corporate updates and program highlights.
-
Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/4/2021
Shattuck Labs, Inc. announced it will host a live webcast presentation highlighting the clinical data being presented at the 2021 Society for Immunotherapy of Cancer on Friday, November 12, 2021 at 8:00 a.m. ET.